title: OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF SUBRETINAL FIBROSIS IN AGE-RELATED MACULAR DEGENERATION.
abstract: OBJECTIVE
  To report the imaging features of subretinal fibrosis secondary to exudative age-related macular degeneration (AMD) on optical coherence tomography angiography.
  
  
  METHODS
  All consecutive patients diagnosed with subretinal fibrosis complicating exudative AMD were imaged by color retinal photographs or multicolor imaging, fluorescein angiography, spectral domain optical coherence tomography, and optical coherence tomography angiography. Eyes with active exudative features observed during the last 6 months were compared with those without any sign of exudation >6 months.
  
  
  RESULTS
  Forty-nine eyes of 47 consecutive patients were included. A blood flow inside the fibrotic scar could be detected in 46 of 49 cases (93.8%). Three patterns of vascular networks could be distinguished, that were described as pruned vascular tree (26 of 49 eyes; 53.1%), tangled network (14 of 49; 28.6%), and/or vascular loop (25 of 49; 51.0%). Furthermore, 2 types of hyporeflective structures, large flow void, and/or dark halo were observed in 63% and in 65% of eyes, respectively. The observed patterns did not differ between eyes with active or inactive lesions.
  
  
  CONCLUSIONS
  Optical coherence tomography angiography of subretinal fibrosis showed almost constantly a perfused, abnormal vascular network and collateral architectural changes in the outer retina and the choriocapillaris layer. These features were associated with both active and inactive fibrotic choroidal neovessels.
authors.affiliation: *Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, Creteil, France; and †Clinical Research Center, GRC Macula, and Biological Ressources Center, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Miere
authors.forename: Oudy
authors.initials: O
authors.lastname: Semoun
authors.forename: Salomon Yves
authors.initials: SY
authors.lastname: Cohen
authors.forename: Ala'a
authors.initials: A
authors.lastname: El Ameen
authors.forename: Mayer
authors.initials: M
authors.lastname: Srour
authors.forename: Camille
authors.initials: C
authors.lastname: Jung
authors.forename: Hassiba
authors.initials: H
authors.lastname: Oubraham
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Querques
authors.forename: Eric H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D005122:Exudates and Transudates; D005260:Female; D005355:Fibrosis; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012039:Regional Blood Flow; D012160:Retina / Q000473:pathology*; D012171:Retinal Vessels / Q000473:pathology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000150:complications* / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A